Price
No data yet.
Social Signal Score
Analyst Ratings
38 analystsRevenue
$2.85B+15.05%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas J. Appio
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 20,300
- Beta
- 0.37
- Country
- CA
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.09
Financials
Revenue
$2.85B+15.0%Net Income
$258.00MEBITDA
$1.02B-7.1%Free Cash Flow
$593.00M+24.1%EPS (diluted)
$0.68Shares Outstanding (diluted)
378.10M+8.2%Operating Expenses
$1.08BCash & Debt
$1.82BReturn of Capital
$0.00Revenue by Segment (annual)
$20.53BDividend per Share
$1.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.27B | $157.00M | $0.43 |
| 2024 | $9.63B | $-46.00M | $-0.13 |
| 2023 | $8.76B | $-592.00M | $-1.62 |
| 2022 | $8.12B | $-225.00M | $-0.62 |
| 2021 | $8.43B | $-948.00M | $-2.61 |
| 2020 | $8.03B | $-559.00M | $-1.57 |
| 2019 | $8.60B | $-1.78B | $-5.06 |
| 2018 | $8.38B | $-4.15B | $-11.86 |
| 2017 | $8.72B | $2.40B | $8.63 |
| 2016 | $9.67B | $-2.41B | $-6.94 |
| 2015 | $10.44B | $-268.66M | $-0.78 |
| 2014 | $8.20B | $881.00M | $3.16 |
| 2013 | $5.77B | $-866.14M | $-2.70 |
| 2012 | $3.48B | $-116.03M | $-0.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.62
- Implied price
- $9.95
- Return from $5.80
- 11.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.95 — -14.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | -4.6% | -1.6% | 1.1% | 3.5% | 5.7% |
| 3.0% | 0.3% | 3.4% | 6.2% | 8.8% | 11.1% |
| 8.0% | 5.2% | 8.5% | 11.4% | 14.1% | 16.5% |
| 13.0% | 10.0% | 13.5% | 16.6% | 19.3% | 21.9% |
| 18.0% | 14.9% | 18.5% | 21.7% | 24.6% | 27.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-25.00%Social Signal Score
Mentions (7)
- Newszacks.com·5d ago·Neutral
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.
View source ↗ - Newszacks.com·14d ago·Positive
Best Value Stocks to Buy for September 22nd BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.
View source ↗ - Newszacks.com·45d ago·Neutral
Can Bausch (BHC) Run Higher on Rising Earnings Estimates? Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newszacks.com·45d ago·Positive
Bausch (BHC) Upgraded to Buy: Here's What You Should Know Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.
View source ↗ - Newszacks.com·55d ago·Positive
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $1.24 per share
Typical surprise -7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.26 vs $0.96beat
- Wed, Apr 29$0.78 vs $0.81miss
- Wed, Feb 18$1.08 vs $1.21miss
- Wed, Oct 29$1.16 vs $1.07beat
- Wed, Jul 30$0.90 vs $0.97miss
- Wed, Apr 30$0.59 vs $0.83miss
Estimates and results for BHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BHC officers and directors.
- Bought
- $385.3m
- Sold
- $726k
9 trades
7 trades
- Lenar Aimee J.sold
- Lee Frank D.sold
- Carson Seanasold
- Carson Seanasold
- Carson Seanasold
- Paulson & Co. Inc.bought
- Carson Seanasold
- Lee Frank D.sold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Susie Leehouse · NV03 · disclosed Oct 7, 2020 (41d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Apr 28, 2020 (64d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Feb 25, 2020 (50d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.